Journal: bioRxiv
Article Title: A chimeric, half-life extended lysin with a unique mode of action
doi: 10.64898/2026.05.13.724763
Figure Lengend Snippet: Efficacy of Fc-CHAP-LSN against in vivo formed biofilms and in sepsis model. (A) Catheters with in vivo formed biofilms of S. aureus ATCC 43300 were explanted from CD1 mice 3 dpi and treated with either 50 µg/mL or 100 µg/mL Fc-L1-CHAP opt -LSN HEKa for 24 h at 37 °C. Rifampicin (10 µg/mL) was used as comparator. (B) Datapoints represent the biofilm bacterial burden in each catheter (n=6). Horizontal bars indicate the median burden for each group. When burden is below LOQ, half a value of LOQ is assigned for graphical and statistical purposes. Brown Forsythe ANOVA with Welch’s correction (GraphPad Prism) was used to calculate statistical significance against vehicle. dpi: days post infection; LOQ: limit of quantification at 10 CFU/catheter. (C) Lysin efficacy in mouse IV sepsis: Immunocompetent male CD1 mice were challenged with 3.23 × 10 7 CFU/mouse of S. aureus NCTC 8178, IV. Lysins were administered IV, twice (1 hpi and 25 hpi) at dose of either 100 µg/mouse or 500 µg/mouse. Vancomycin (Van) was dosed at 25 mg/kg, IV, q12 h, starting from 1 hpi. (D) Points on the graph represent CFU counts in individual mice (n=6), with horizontal lines indicating median CFU burden and interquartile range. Open circles indicate animals that needed to be terminated before planned endpoint due to clinical symptoms. Brown-Forsythe ANOVA with Welch’s correction was used to calculate the significance compared to vehicle group on log transformed data, with P values indicated in the graph. hpi: hours post infection; CFU: colony forming units; LOQ: limit of quantification at 54 CFU/g; For graphical and statistical purposes, values under LOQ were assigned half of the LOQ value.
Article Snippet: SPF (specific pathogen free) CD1 mice used in this work were supplied by Charles River Laboratories (Margate, UK).
Techniques: In Vivo, Infection, Transformation Assay
